AXSM Dividend: Axsome Therapeutics Inc Yield Insights

Income

Balance sheet

Cash flow

Annual

Quarterly

AXSM Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	561	385	270	50	0	0
Revenue Growth (YoY)	66%	43%	440%	--	--	--
Cost of Revenue	45	33	26	5	--	--
Gross Profit	515	352	244	44	--	--
Selling, General & Admin	516	411	323	158	66	28
Research & Development	189	187	97	57	58	70
Operating Expenses	730	632	476	224	124	99
Other Non Operating Income (Expenses)	--	--	--	0	0	0
Pretax Income	-230	-287	-238	-187	-130	-102
Income Tax Expense	0	0	0	--	--	--
Net Income	-229	-287	-239	-187	-130	-102
Net Income Growth	-26%	20%	28%	44%	27%	50%
Shares Outstanding (Diluted)	50.02	47.91	45.42	40.66	37.62	37.21
Shares Change (YoY)	4%	5%	12%	8%	1%	9%
EPS (Diluted)	-4.58	-5.99	-5.26	-4.6	-3.47	-2.77
EPS Growth	-28.99%	14%	14%	33%	25%	38%
Free Cash Flow	-101	-128	-145	-117	-108	-78
Free Cash Flow Per Share	-2.01	-2.67	-3.19	-2.87	-2.87	-2.09
Gross Margin	91.8%	91.42%	90.37%	88%	--	--
Operating Margin	-38.14%	-72.72%	-85.55%	-358%	0%	0%
Profit Margin	-40.81%	-74.54%	-88.51%	-374%	0%	0%
Free Cash Flow Margin	-18%	-33.24%	-53.7%	-234%	0%	0%
EBITDA	-208	-274	-225	-175	-124	-99
EBITDA Margin	-37.07%	-71.16%	-83.33%	-350%	0%	0%
D&A For EBITDA	6	6	6	4	0	0
EBIT	-214	-280	-231	-179	-124	-99
EBIT Margin	-38.14%	-72.72%	-85.55%	-358%	0%	0%
Effective Tax Rate	0%	0%	0%	--	--	--